Muhammad Ali

Education & Training

---

• Ph.D.: University of Luxembourg, 2019
• M.S.: Universität des Saarlandes, 2014
• M.S.: Government College University, Faisalabad, 2013
• B.S.: Government College University, Faisalabad, 2010

Major Awards

---

• EURON Mobility Grant, 2019
• Joint Programme – Neurodegenerative Disease (JPND) Doctoral Fellowship, 2015

View clinician profile

Research Interests

---

Dr. Muhammad Ali is an Assistant Professor in the Department of Psychiatry at Washington University School of Medicine in St. Louis (WashU). His research focuses on identifying biomarkers and therapeutic targets for neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD). His work leverages large-scale, multi-platform proteomic datasets to uncover disease-specific and shared molecular signatures across tissues (cerebrospinal fluid and plasma) and disease stages.

Visit lab website

Recent Publications

---

• Data-driven clinical decision support tool for diagnosing mild cognitive impairment in Parkinson’s disease

  NCER-PD Consortium, Dec 2026, In: npj Parkinson’s Disease. 12, 1, 15.

• OMG! A proteomic determinant of neurodegenerative resiliency

  Duggan, M. R., Oh, H. S. H., Frank, P., Gomez, G. T., Zweibaum, D., Cui, Y., Chen, J., Surapaneni, A., Blew, C. O., Dark, H. E., Joynes, C. M., Kandala, S., Bilgel, M., Farinas, A., Erus, G., Tian, Q., Candia, J., Pucha, K. A., Landman, B. A. & Dumitrescu, L. & 36 others, Hohman, T. J., Lewis, A., Moghekar, A., Siavoshi, F., Ali, M., Liu, M., Xu, Y., Western, D., Kaneko, N., Kato, S., Furuichi, M., Shibayama, M., Katsuno, M., Nishita, Y., Otsuka, R., Gottesman, R. F., Dammer, E. B., Seyfried, N. T., Levey, A. I., Erik, E. C., Mormino, E., Wagner, A. D., Poston, K. L., Kapogiannis, D., Grams, M. E., Bhargava, P., Waga, I., Davatzikos, C., Resnick, S. M., Ferrucci, L., Bennett, D. A., Cruchaga, C., Wyss-Coray, T., Kivimäki, M., Coresh, J. & Walker, K. A., Dec 2026, In: Molecular neurodegeneration. 21, 1, 9.

• Large-scale CSF and plasma proteomics reveal immune, synaptic, and extracellular matrix disruptions across neurodegenerative diseases

  Knight Alzheimer Disease Research Center (Knight ADRC), Alzheimer Disease Neuroimaging Initiative (ADNI), Fundació ACE Alzheimer Center Barcelona (FACE), Barcelona-1, Stanford Alzheimer Disease Research Center (Stanford ADRC) & The Global Neurodegeneration Proteomics Consortium (GNPC), Jul 15 2026, In: Neuron. 114, 14, p. 2549-2565.e7

• Blood-based proteomic signature of amyloidosis: identification of novel regulators of amyloid load

  Knight Alzheimer Disease Research Center (Knight ADRC), Jun 2026, In: Alzheimer’s and Dementia. 22, 6, e71611.

• APOE-stratified Proteomic and Metabolomic Analysis Reveals Mitochondrial Dysfunction Inflammation and Lipid Dysregulation in Alzheimer’s Disease

  Li, F., Chen, Y., Western, D., Ali, M., Liu, M., Gong, K., Xu, Y., Lowery, J., Holtzman, D. M., Robins, C., Eicher, J. D., Huang, Y. N., Liu, S. W., Park, T., Saykin, A. J., Nho, K., Moqri, M., Mohs, R. C., Farinas, A. & Moran-Losada, P. & 3 others, Oh, H. S. H., Wyss-Coray, T. & Cruchaga, C., Apr 13 2026, In: Advanced Science. 13, 21, e13872.

See more publications